Zydus Lifesciences Ltd (BOM:532321) reports a robust 17% revenue increase and significant advancements in its innovation pipeline amidst market challenges.

The company's India business, comprising both formulations and consumer wellness divisions, contributed 38 per cent of ...

Zydus Lifesciences Limited reports 30% profit increase, driven by US formulations business, with strong financial position ...

The United States is the company's biggest market accounting for 47 per cent of total revenue, followed by India ...

Zydus Lifesciences on Wednesday said consolidated net profit increased by 30 per cent to Rs 1,023 crore for the third quarter ended December 31, 2024, aided by robust sales across domestic and US ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

The early morning operation targets multiple properties in Dover, Deal, Thanet and Aylesham. A report says the existing facility in Hartlepool's Whitby Street is in a deteriorating condition.

Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term. The generic Revlimid opportunity was significant but will end by FY27, ...

Zydus Lifesciences Ltd. said on Wednesday that the US Food and Drug Administration granted its underdevelopment drug Usnoflast the orphan drug designation, according to an exchange filing on Wednesday ...